Clinical pharmacokinetics of drugs against onchocerciasis
Orme, M.; Edwards, G.; Awadzi, K.; Breckenridge, A.
Acta Leidensia 59(1-2): 329-342
1990
ISSN/ISBN: 0065-1362 PMID: 2198757 Document Number: 148
We now have the ability to measure small amounts of anti filarial drugs in plasma and other biological fluids. However in many cases knowledge about the kinetics of these drugs in human is not well advanced and this may be limiting the clinical progress with the drugs since they are unlikely to be being used to optimum effect.
Document emailed within 1 workday
Related Documents
Awadzi, K.; Hero, M.; Opoku, N.O.; Büttner, D.W.; Coventry, P.A.; Prime, M.A.; Orme, M.L.; Edwards, G. 1994: The chemotherapy of onchocerciasis XVII. A clinical evaluation of albendazole in patients with onchocerciasis; effects of food and pretreatment with ivermectin on drug response and pharmacokinetics Tropical Medicine and Parasitology: Official Organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft für Technische Zusammenarbeit 45(3): 203-208Sams, R.A. 1984: Principles of clinical pharmacokinetics of antimicrobial drugs Journal of the American Veterinary Medical Association 185(10): 1068-1071
Hirtz, J.; Schoeller, J.P. 1976: Clinical value of the determination of drugs in the blood: a new aspect of pharmacokinetics La Nouvelle Presse Medicale 5(13): 869-872
Kaye, S.B.; Workman, P.; Graham, M.A.; Cassidy, J.; Jodrell, D. 1993: Pharmacokinetics and early clinical studies of selected new drugs Cancer Surveys 17: 371-396
Van der Kleijn, E.; Baars, A.M.; Vree, T.B.; van der Dries, A. 1983: Clinical pharmacokinetics of drugs used in the treatment of status epilepticus Advances in Neurology 34: 421-440
Ovusu, A.; Lur'e, A.A.; Petrov, O.E.; Ozeretskovskaia, N.N. 1984: Pharmacokinetics of anti-onchocerciasis preparations. 1. Suramin in standard and decreased doses Meditsinskaia Parazitologiia i Parazitarnye Bolezni 5: 40-44
Brøsen, K. 1991: The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs Ugeskrift for Laeger 153(6): 417-422
Lecaillon, J.B.; Poltera, A.A.; Zea-Flores, G.; de Ramirez, I.; Nowell de Arevalo, A. 1991: Influence of food related to dose on the pharmacokinetics of amocarzine and of its N-oxide metabolite, CGP 13 231, after oral administration to 20 onchocerciasis male patients from Guatemala Tropical Medicine and Parasitology: Official Organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft für Technische Zusammenarbeit 42(3): 286-290
Noma, M.; Nwoke, B.E.B.; Nutall, I.; Tambala, P.A.; Enyong, P.; Namsenmo, A.; Remme, J.; Amazigo, U.V.; Kale, O.O.; Seketeli, A. 2002: Rapid epidemiological mapping of onchocerciasis Its application by the African Programme for Onchocerciasis Control Annals of Tropical Medicine and Parasitology 96(Suppl 1): S29-S39
2009: Onchocerciasis (river blindness). Report from the eighteenth InterAmerican Conference on Onchocerciasis, November 2008 Releve Epidemiologique Hebdomadaire 84(38): 385-389
Carabin, Hélène.; Escalona, M.; Marshall, C.; Vivas-Martínez, S.; Botto, C.; Joseph, L.; Basáñez, Mía-Gloria. 2003: Prediction of community prevalence of human onchocerciasis in the Amazonian onchocerciasis focus: Bayesian approach Bulletin of the World Health Organization 81(7): 482-490
Colebunders, R.; Raimon, S.; Siewe Fodjo, J.N.; Carter, J.Y. 2019: Increased cost-benefit of strengthening onchocerciasis elimination efforts in areas with high onchocerciasis-associated epilepsy Tropical Medicine and International Health: Tm and Ih 24(10): 1259
Gutteridge, W.E.; Hudson, A.T.; Jenkins, D.C. 1990: The Wellcome Foundation/World Health Organisation Onchocerciasis Chemotherapy Project Joint Programme to discover and develop a macrofilaricide for onchocerciasis Acta Leidensia 59(1-2): 343-360
Remme, J.; Ba, O.; Dadzie, K.Y.; Karam, M. 1986: A force-of-infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River basin area Bulletin of the World Health Organization 64(5): 667-681
Evans, D.S.; Alphonsus, K.; Umaru, J.; Eigege, A.; Miri, E.; Mafuyai, H.; Gonzales-Peralta, C.; Adamani, W.; Pede, E.; Umbugadu, C.; Saka, Y.; Okoeguale, B.; Richards, F.O. 2014: Status of Onchocerciasis transmission after more than a decade of mass drug administration for onchocerciasis and lymphatic filariasis elimination in central Nigeria: challenges in coordinating the stop MDA decision PLOS Neglected Tropical Diseases 8(9): E3113
Paxton, J.W. 1981: Elementary pharmacokinetics in clinical practice 4: genetic, environmental and age influences on pharmacokinetics New Zealand Medical Journal 94(697): 423-425
Molyneux, D.H. 1995: Onchocerciasis control in West Africa: current status and future of the Onchocerciasis Control Programme Parasitology Today 11(11): 399-402, 406
Fazen, L.E.; Anderson, R.I.; Fazen, L.E.; Marroquin, H.F. 1976: Clinical and laboratory changes consequent to diethylcarbamazine in patients with onchocerciasis American Journal of Tropical Medicine and Hygiene 25(2): 250-256
Kock-Weser, J. 1975: Pharmacokinetics of antiarrhythmic drugs Cardiovascular Clinics 7(2): 191-202
Bernareggi, A. 1995: Pharmacokinetics of chiral drugs Bollettino Chimico Farmaceutico 134(2): 63-68